Lyell Immunopharma announced it will present updated safety and translational data from its Phase 1/2 trial of ronde-cel, a dual-targeting CD19/CD20 CAR T-cell therapy for relapsed or refractory large B-cell lymphoma, at the European Hematology Association 2026 Congress. The data includes an updated safety analysis and insights into the therapy's durable responses linked to cytotoxic T cells with memory potential. Ronde-cel is being evaluated in two pivotal trials for second- and third-line treatment settings, with key data expected in late 2026 and mid-2027, supporting a potential Biologics License Application submission in 2027. This progress highlights Lyell's advancement in next-generation CAR T therapies for cancer treatment.
Ethereum futures long positions among top traders increased by over 3 percentage points across both USDT- and coin-margined markets, indicating a broad-based shift in short-term sentiment. This rise suggests heightened attention on ETH compared to ot...
NVIDIA announced that leading Japanese companies in robotics and manufacturing are adopting its Cosmos, Isaac, Metropolis, and Jetson platforms to accelerate AI-powered intelligent machines across industries. The new Cosmos 3 Edge model enables real-...
Oil prices are rising sharply due to renewed US naval blockades on Iranian shipping and increased tensions in the Strait of Hormuz, a critical oil transit route. Brent crude is holding above $85 and WTI above $80, with forecasts suggesting WTI could ...
The US government announced it will impose a new 25% tariff on Brazilian ethanol starting next Wednesday, accusing Brazil of unfair trade practices. This tariff excludes major Brazilian exports like oil, beef, coffee, and aircraft parts. The move fol...
Alibaba and Baidu shares rose after Apple received approval from China's Cyberspace Administration to include Apple Intelligence, integrating Alibaba's Qwen AI model and Baidu's AI features into Apple devices in China. This partnership allows users t...
